Tue Sep 10 14:17:00 UTC 2024: ## Remedium Bio Secures Investment for Adjustable-Dose Gene Therapy Platform

**NORWALK, Conn., Sept. 10, 2024** – Remedium Bio, a biotechnology company developing a novel gene therapy platform, announced today that it has received an investment from LifeSpan Vision Ventures. This funding will be used to advance the company’s lead candidate, RMD-1202, towards Phase 1 clinical trials.

Remedium’s Prometheus™ platform utilizes a single, adjustable-dose gene therapy injection to replace a wide range of multi-protein injection treatments. This approach offers several advantages over traditional protein injections, including:

* **Durability and Consistency:** Prometheus™ delivers stable and consistent protein expression, eliminating concentration spikes that can compromise safety and efficacy.
* **Safety and Tolerability:** The localized and subcutaneous delivery method provides a safe and well-tolerated treatment option.
* **Cost-Effectiveness:** The single-injection approach has the potential to significantly reduce costs compared to repeated protein injections.

RMD-1202, Remedium’s lead candidate, targets the GLP-1 receptor, demonstrating superior weight loss, glycemic control, and insulin response compared to daily GLP-1 protein injections. The company is also developing additional therapies across musculoskeletal, immunology, and neurology disorders.

“Our mission is to invest in companies that support and accelerate the development of therapies that extend healthspan,” said Andrew Worden, Founding Partner at LifeSpan Vision Ventures. “We believe Remedium’s technology can be applied across a broad range of age-related diseases and opens the potential of gene therapy to vast markets.”

“We are thrilled to have LifeSpan Vision Ventures on board as an investor,” stated Frank Luppino, President and CEO of Remedium Bio. “Their expertise and commitment to advancing longevity solutions make them an ideal partner as we enter this exciting new phase of growth.”

Remedium’s Prometheus™ platform represents a significant advancement in genetic medicine, potentially revolutionizing the treatment of a wide range of age-related diseases. This investment signifies a key step towards bringing this innovative technology to market and improving the lives of countless individuals.

Read More